Cyclacel Pharmaceuticals, Inc. (CYCC)

US — Healthcare Sector

Peers: ELYM IKNA OVID CNTB EWTX RZLT CYT XOMAO PTIX TPST OVIT NTII GNCAQ POLXF CBIO MBRX PULM AKTX NXTC CTMX NLTX SPRO ASMB

Automate Your Wheel Strategy on CYCC

With Tiblio's Option Bot, you can configure your own wheel strategy including CYCC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol CYCC
Rev/Share -0.0016
Book/Share 0.2363
PB 1.3848
Debt/Equity 0.0029
CurrentRatio 5.6018
ROIC -4.4345

MktCap 7287497.0
FreeCF/Share -0.5795
PFCF -0.9703
PE -0.508
Debt/Assets 0.0024
DivYield 7.335
ROE -36.41

Rating C+
Score 2
Recommendation Sell
P/E Score 1
DCF Score 5
P/B Score 1
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCC, CYCCP
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series F Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $3.0 million before deducting offering expenses. In connection with the offering, Cyclacel issued to each investor, a series A common stock purchase warrant to purchase 3,270,000 shares of the Company's common stock, par value $0.001 per share (“Common Stock”) at an …

image for news Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCC, CYCCP
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884.

image for news CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

CYCC, CYCCP
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estate development and construction.

image for news CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

CYCC, CYCCP
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series E Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $1.0 million before deducting offering expenses. The offering closed on March 21, 2025.

image for news Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

CYCC, CYCCP
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.

image for news Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

About Cyclacel Pharmaceuticals, Inc. (CYCC)

IPO Date 2004-03-16
Website https://www.cyclacel.com
Industry Biotechnology
CEO Dr. Sing Ee Wong
Employees 12

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.